In a dose-dependent manner, RGS favors the proliferation and activation of tumor-infiltrating T cells (especially CD8+ cytotoxic T cells [Tc]), and the induction of NK cells, along with a reduction in M2-like macrophages in the TME. The gene discussed is CD8A; the disease is neoplasm.